SlideShare ist ein Scribd-Unternehmen logo
1 von 31
ANTIDEPRESSANTS
Samaiya Mushtaq
CHEM 5398
DEPRESSION
 Types
 Symptoms

 Diagnosis

 Causes

 Treatment
TYPES OF DEPRESSION
           Major depression
           Chronic depression (Dysthymia)

           Atypical depression

           Bipolar disorder/Manic depression

           Seasonal depression (SAD)
SYMPTOMS
   persistently sad, anxious, or empty moods
   loss of pleasure in usual activities (anhedonia)
   feelings of helplessness, guilt, or worthlessness
   crying, hopelessness, or persistent pessimism
   fatigue or decreased energy
   loss of memory, concentration, or decision-making capability
   restlessness, irritability
   sleep disturbances
   change in appetite or weight
   physical symptoms that defy diagnosis and do not respond to
    treatment (especially pain and gastrointestinal complaints)
   thoughts of suicide or death, or suicide attempts
   poor self-image or self-esteem (as illustrated, for example, by
    verbal self-reproach)
DIAGNOSIS
 Extensive patient and family history
 Blood test for hypothyroidism

 Current medication

 DSM-IV
     One  of the first two symptoms
     Five other symptoms
CAUSES OF DEPRESSION
 Genetics
 Death/Abuse

 Medications
TREATMENT FOR DEPRESSION
 Psychotherapy
 Electroconvulsive therapy

 Natural alternatives

 Medication
      SSRIs
      MAOIs

      TCAs

      SNRIs

      NDRIs

      TeCAs
NEUROTRANSMITTERS AND THE
CATECHOLAMINE HYPOTHESIS
 Neurotransmitters pass along signal
 Smaller amount of neurotransmitters causes
  depression
MONOAMINE OXIDASE (MAO) AND
DEPRESSION
   MAO catalyze deamination of intracellular
    monoamines
     MAO-A   oxidizes epinephrine, norepinephrine,
      serotonin
     MAO-B oxidizes phenylethylamine
     Both oxidize dopamine nonpreferentially
   MAO transporters reuptake extracellular
    monoamine
MONOAMINE OXIDASE INHIBITORS
(MAOIS)
   History
     Isoniazid
     Iproniazid
 Current Drugs
 Mechanism of Action

 Side Effects          Isoniazid




                        Iproniazid
MAOIS ON THE MARKET
   MAO Inhibitors (nonselective)
     Phenelzine (Nardil)
     Tranylcypromine (Parnate)
     Isocarboxazid (Marplan)
   MAO-B Inhibitors (selective for MAO-B)
     Selegiline   (Emsam)
MAOIS MECHANISM OF ACTION
 MAO contains a
  cysteinyl-linked
  flavin
 MAOIs covalently
  bind to N-5 of the
  flavin residue of
  the enzyme
MAOIS SIDE EFFECTS
MAOIS SIDE EFFECTS
 Side effects have put MAOIs in the second or
  third line of defense despite superior efficacy
 MAO-A inhibitors interfere with breakdown of
  tyramine
     High tyramine levels cause hypertensive crisis (the
      “cheese effect”)
     Can be controlled with restricted diet
   MAOIs interact with certain drugs
     Serotoninsyndrome (muscle rigidity, fever, seizures)
     Pain medications and SSRIs must be avoided
THE RECEPTOR SENSITIVITY
HYPOTHESIS
 Supersensitivity and up-regulation of post-
  synaptic receptors leads to depression
 Suicidal and depressed patients have increased
  5HT-α2 receptors
TRICYCLIC ANTIDEPRESSANTS
(TCAS)
   History
     Imipramine
 Current Drugs
 Mechanism of Action

 Side Effects




                        Imipramine
TCAS ON THE MARKET
 Amitriptyline
 Desipramine (Norpramin)

 Doxepin (Sinequan)

 Imipramine (Tofranil, Tofranil-PM)

 Nortriptyline (Pamelor)

 Protriptyline (Vivactil)

 Trimipramine (Surmontil)
TCAS MECHANISM OF ACTION
 TCAs inhibit serotonin,
  norepinephrine, and dopamine
  transporters, slowing reuptake
 TCAs also allow for the
  downregulation of post-
  synaptic receptors
 All TCAs and SSRIs contain
  an essential amino group that
  appears to interact with Asp-
  98 in hSERT
TCAS SIDE EFFECTS
   Muscarinic M1 receptor antagonism - anticholinergic
    effects including dry mouth, blurred vision,
    constipation, urinary retention and impotence
   Histamine H1 receptor antagonism - sedation and
    weight gain
   Adrenergic α receptor antagonism - postural
    hypotension
   Direct membrane effects - reduced seizure threshold,
    arrhythmia
   Serotonin 5-HT2 receptor antagonism - weight gain
    (and reduced anxiety)
TCAS SIDE EFFECTS
 Nonselectivity results in
  greater side effects
 TCAs can also lead to
  cardiotoxicity
     Increased LDH leakage
     Slow cardiac conduction
   High potency can lead to
    mania
     Contraindicated with
      persons with bipolar
      disorder or manic depression
TETRACYCLIC ANTIDEPRESSANTS
(TECAS)
   Current Drugs
     Mirtazapine   (Remeron)
   Mechanism of Action
     Same   as TCAs
   Side Effects
SELECTIVE SEROTONIN REUPTAKE
INHIBITORS
 Most commonly prescribed class
 Current drugs

 Mechanism of action

 Side effects




                                   Serotonin
SSRIS ON THE MARKET
 citalopram (Celexa)
 dapoxetine (Priligy)

 escitalopram (Lexapro)

 fluoxetine (Prozac)

 fluvoxamine (Luvox)                  Fluoxetine 1:1

 paroxetine (Paxil)

 sertraline (Zoloft)

 zimelidine (Zelmid) (discontinued)

 indalpine (Upstene) (discontinued)


                                          Sertraline
SSRIS MECHANISM OF ACTION
 Exact mechanism remains uncertain
 Ser-438 residue in the human serotonin
  transporter (hSERT) appears to be a determining
  factor in SSRI potency
 Antidepressants interact directly with hSERT

 http://www.mayoclinic.com/health/antidepressants/MM0066
SSRIS SIDE EFFECTS
SSRIS SIDE EFFECTS
 Many disappear within 4 weeks (adaption phase)
 Side effects more manageable compared to
  MAOIs and TCAs
 Sexual side effects are common

 SSRI cessation syndrome
     Brainzaps
     Sexual dysfunction
SEROTONIN-NOREPINEPHRINE
REUPTAKE INHIBITORS (SNRIS)
 Slightly greater efficacy than SSRIs
 Slightly fewer adverse effects than SSRIs

 Current drugs
     Venlafaxine (Effexor)
     Duloxetine (Cymbalta)
   Mechanism of Action
     Verysimilar to SSRIs
     Works on both neurotransmitters
                                        Venlafaxine 1:1
   Side effects                        Duloxetine
     Similar   to SSRIs
     Suicide
NOREPINEPHRINE-DOPAMINE
REUPTAKE INHIBITORS (NDRIS)
   Current drugs
     Bupropion    (Wellbutrin)
   Mechanims of Action
     Similar to SSRIs and SNRIs
     More potent in inhibiting dopamine
     Also anα3-β4 nicotinic antagonist
                                               Bupropion 1:1
   Adverse effects
     Lowers    seizure threshold
     Suicide
     Does not cause weight gain or sexual dysfunction
      (even used to treat the two)
REFERENCES
   http://ajp.psychiatryonline.org/cgi/reprint/157/11/1901
   http://www.webmd.com/depression/
   http://pn.psychiatryonline.org/content/41/24/21.full
   http://www.mayoclinic.com/health/maois/MH00072
   http://www.springerlink.com/content/b9b8668ff59f89d7/fulltext.pdf
   http://www.emsam.com/pi_emsam.pdf
   http://www.nevdgp.org.au/info/topics/depression_theory.htm
   http://www.uspharmacist.com/content/t/psychotropic_disorders/c/11467/
   http://www.jbc.org/content/284/15/10276.full.pdf+html
   http://www.aafp.org/afp/981200ap/cadieux.html
   http://www.mayoclinic.com/health/antidepressants/MH00071
   http://books.google.com/books?
    id=R0W1ErpsQpkC&pg=PA565&lpg=PA565&dq=tcas+mechanism+of+action&source=bl&ots=oAS
    le2Z-
    pr&sig=36CB_3JY4uD3LIYvqXWmAb3nliY&hl=en&ei=HzfFS9OrB4Tu9gTD6_ixDg&sa=X&oi=bo
    ok_result&ct=result&resnum=8&ved=0CCoQ6AEwBw#v=onepage&q=tcas%20mechanism%20of
    %20action&f=false
   http://www.informaworld.com/smpp/content~content=a916036122&db=all

Weitere ähnliche Inhalte

Was ist angesagt?

Antidepressants: Mechanisms based classification & challenges in therapeutic ...
Antidepressants: Mechanisms based classification & challenges in therapeutic ...Antidepressants: Mechanisms based classification & challenges in therapeutic ...
Antidepressants: Mechanisms based classification & challenges in therapeutic ...DrAshok Batham
 
Antidepressant drugs
Antidepressant drugsAntidepressant drugs
Antidepressant drugsDaniel Wang
 
Selective serotonin re-uptake inhibitors (SSRIs)
Selective serotonin re-uptake inhibitors (SSRIs)Selective serotonin re-uptake inhibitors (SSRIs)
Selective serotonin re-uptake inhibitors (SSRIs)DilanDavisM
 
Anti depressant ( fluoxetine)
Anti depressant ( fluoxetine)Anti depressant ( fluoxetine)
Anti depressant ( fluoxetine)Rifat Zakir
 
Selective serotonin reuptake inhibitors 2016
Selective serotonin reuptake inhibitors 2016Selective serotonin reuptake inhibitors 2016
Selective serotonin reuptake inhibitors 2016Mohamed Sedky
 
Mahi anti depressants
Mahi anti depressantsMahi anti depressants
Mahi anti depressantsMahi Yeruva
 
General psychopharmacology
General psychopharmacologyGeneral psychopharmacology
General psychopharmacologySalman Kareem
 
Antidepressants, pharmacokinetics
Antidepressants, pharmacokineticsAntidepressants, pharmacokinetics
Antidepressants, pharmacokineticsDomina Petric
 
Anti-depressant drugs. Dr. Ashok Kumar Batham,M.D.,
Anti-depressant drugs. Dr. Ashok Kumar Batham,M.D.,Anti-depressant drugs. Dr. Ashok Kumar Batham,M.D.,
Anti-depressant drugs. Dr. Ashok Kumar Batham,M.D.,DrAshok Batham
 

Was ist angesagt? (20)

Antidepressants: Mechanisms based classification & challenges in therapeutic ...
Antidepressants: Mechanisms based classification & challenges in therapeutic ...Antidepressants: Mechanisms based classification & challenges in therapeutic ...
Antidepressants: Mechanisms based classification & challenges in therapeutic ...
 
Ssri n snri
Ssri n snriSsri n snri
Ssri n snri
 
Antidepressant drugs
Antidepressant drugsAntidepressant drugs
Antidepressant drugs
 
Selective serotonin re-uptake inhibitors (SSRIs)
Selective serotonin re-uptake inhibitors (SSRIs)Selective serotonin re-uptake inhibitors (SSRIs)
Selective serotonin re-uptake inhibitors (SSRIs)
 
SSRIs
SSRIsSSRIs
SSRIs
 
Anti depressant ( fluoxetine)
Anti depressant ( fluoxetine)Anti depressant ( fluoxetine)
Anti depressant ( fluoxetine)
 
Selective serotonin reuptake inhibitors 2016
Selective serotonin reuptake inhibitors 2016Selective serotonin reuptake inhibitors 2016
Selective serotonin reuptake inhibitors 2016
 
Mahi anti depressants
Mahi anti depressantsMahi anti depressants
Mahi anti depressants
 
Ssri.ppt 2013
Ssri.ppt 2013Ssri.ppt 2013
Ssri.ppt 2013
 
Anti depressants
Anti depressantsAnti depressants
Anti depressants
 
Paxil
PaxilPaxil
Paxil
 
General psychopharmacology
General psychopharmacologyGeneral psychopharmacology
General psychopharmacology
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
 
Depression
DepressionDepression
Depression
 
Anti depressant drugs
Anti depressant drugsAnti depressant drugs
Anti depressant drugs
 
Antidepressants, pharmacokinetics
Antidepressants, pharmacokineticsAntidepressants, pharmacokinetics
Antidepressants, pharmacokinetics
 
Antidepressants Update
Antidepressants UpdateAntidepressants Update
Antidepressants Update
 
Anti-depressant drugs. Dr. Ashok Kumar Batham,M.D.,
Anti-depressant drugs. Dr. Ashok Kumar Batham,M.D.,Anti-depressant drugs. Dr. Ashok Kumar Batham,M.D.,
Anti-depressant drugs. Dr. Ashok Kumar Batham,M.D.,
 
Anti-Depressant
Anti-Depressant Anti-Depressant
Anti-Depressant
 
Pp antidepressants final
Pp antidepressants finalPp antidepressants final
Pp antidepressants final
 

Ähnlich wie Αντικαταθλιπτικα

Antidepressants.ppt
Antidepressants.pptAntidepressants.ppt
Antidepressants.pptImtiyaz60
 
Antidepressants.ppt
Antidepressants.pptAntidepressants.ppt
Antidepressants.pptImtiyaz60
 
antidepressantS-THAMIZH.ppt
antidepressantS-THAMIZH.pptantidepressantS-THAMIZH.ppt
antidepressantS-THAMIZH.pptThamizh Arasan
 
Antidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptAntidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptAmanDeepTiwari4
 
Antidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptAntidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptssuserc71950
 
Antidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptAntidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptImtiyaz60
 
Antidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptAntidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptprince1123
 
Antidepressant drugs
Antidepressant drugsAntidepressant drugs
Antidepressant drugsAmira Badr
 
Antidepressant drugs
Antidepressant drugsAntidepressant drugs
Antidepressant drugsAmira Badr
 
Anti depressants
Anti depressantsAnti depressants
Anti depressantsraj kumar
 
NurseReview.Org - Psychotherapeutic Agents Updates (lesson 1 pharmacology)
NurseReview.Org - Psychotherapeutic Agents Updates (lesson 1 pharmacology)NurseReview.Org - Psychotherapeutic Agents Updates (lesson 1 pharmacology)
NurseReview.Org - Psychotherapeutic Agents Updates (lesson 1 pharmacology)jben501
 
06 Psychotherapeutic Agents Upd
06 Psychotherapeutic Agents Upd06 Psychotherapeutic Agents Upd
06 Psychotherapeutic Agents UpdNurse Uragon
 
Anti depressant , antidepressant
Anti depressant , antidepressantAnti depressant , antidepressant
Anti depressant , antidepressantRavish Yadav
 

Ähnlich wie Αντικαταθλιπτικα (20)

Antidepressants.ppt
Antidepressants.pptAntidepressants.ppt
Antidepressants.ppt
 
Antidepressants.ppt
Antidepressants.pptAntidepressants.ppt
Antidepressants.ppt
 
antidepressantS-THAMIZH.ppt
antidepressantS-THAMIZH.pptantidepressantS-THAMIZH.ppt
antidepressantS-THAMIZH.ppt
 
New Antidepressant Dr.Rahul.pptx
New Antidepressant Dr.Rahul.pptxNew Antidepressant Dr.Rahul.pptx
New Antidepressant Dr.Rahul.pptx
 
Seminar On Antidepressants
Seminar On AntidepressantsSeminar On Antidepressants
Seminar On Antidepressants
 
Antidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptAntidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.ppt
 
Antidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptAntidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.ppt
 
Antidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptAntidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.ppt
 
Antidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptAntidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.ppt
 
Antidepressant drugs
Antidepressant drugsAntidepressant drugs
Antidepressant drugs
 
Antidepressant drugs
Antidepressant drugsAntidepressant drugs
Antidepressant drugs
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
 
Pharma Nervous Day 2.pptx
Pharma Nervous Day 2.pptxPharma Nervous Day 2.pptx
Pharma Nervous Day 2.pptx
 
Anti depressants
Anti depressantsAnti depressants
Anti depressants
 
Anti depressants
Anti depressantsAnti depressants
Anti depressants
 
phants
phantsphants
phants
 
NurseReview.Org - Psychotherapeutic Agents Updates (lesson 1 pharmacology)
NurseReview.Org - Psychotherapeutic Agents Updates (lesson 1 pharmacology)NurseReview.Org - Psychotherapeutic Agents Updates (lesson 1 pharmacology)
NurseReview.Org - Psychotherapeutic Agents Updates (lesson 1 pharmacology)
 
Antidepressant
AntidepressantAntidepressant
Antidepressant
 
06 Psychotherapeutic Agents Upd
06 Psychotherapeutic Agents Upd06 Psychotherapeutic Agents Upd
06 Psychotherapeutic Agents Upd
 
Anti depressant , antidepressant
Anti depressant , antidepressantAnti depressant , antidepressant
Anti depressant , antidepressant
 

Mehr von Institute for the Study of Urologic Diseases

Andrology Update 2020 | Διαγνωστικά και Θεραπευτικά Πρωτόκολλα στην Ανδρολογί...
Andrology Update 2020 | Διαγνωστικά και Θεραπευτικά Πρωτόκολλα στην Ανδρολογί...Andrology Update 2020 | Διαγνωστικά και Θεραπευτικά Πρωτόκολλα στην Ανδρολογί...
Andrology Update 2020 | Διαγνωστικά και Θεραπευτικά Πρωτόκολλα στην Ανδρολογί...Institute for the Study of Urologic Diseases
 
10ο Ελληνικό Διαδραστικό Σχολείο Ουρολογίας | Πρόγραμμα
10ο Ελληνικό Διαδραστικό Σχολείο Ουρολογίας | Πρόγραμμα 10ο Ελληνικό Διαδραστικό Σχολείο Ουρολογίας | Πρόγραμμα
10ο Ελληνικό Διαδραστικό Σχολείο Ουρολογίας | Πρόγραμμα Institute for the Study of Urologic Diseases
 
9ο Ελληνικό Διαδραστικό Σχολείο Ουρολογίας | Πρόγραμμα `
9ο Ελληνικό Διαδραστικό Σχολείο Ουρολογίας | Πρόγραμμα `9ο Ελληνικό Διαδραστικό Σχολείο Ουρολογίας | Πρόγραμμα `
9ο Ελληνικό Διαδραστικό Σχολείο Ουρολογίας | Πρόγραμμα `Institute for the Study of Urologic Diseases
 
Κλινικές δεξιότητες στην Ανδρολογία - Andrology Update 2016 | Πρόγραμμα
 Κλινικές δεξιότητες στην Ανδρολογία - Andrology Update 2016 | Πρόγραμμα Κλινικές δεξιότητες στην Ανδρολογία - Andrology Update 2016 | Πρόγραμμα
Κλινικές δεξιότητες στην Ανδρολογία - Andrology Update 2016 | ΠρόγραμμαInstitute for the Study of Urologic Diseases
 
5o Κλινικό Φροντιστήριο Λειτουργικής Ουρολογίας :: Andrology Update 2015
5o Κλινικό Φροντιστήριο Λειτουργικής Ουρολογίας :: Andrology Update 20155o Κλινικό Φροντιστήριο Λειτουργικής Ουρολογίας :: Andrology Update 2015
5o Κλινικό Φροντιστήριο Λειτουργικής Ουρολογίας :: Andrology Update 2015Institute for the Study of Urologic Diseases
 
Θεραπείες στυτικής δυσλειτουργίας - Τα κάτω, πάνω
Θεραπείες στυτικής δυσλειτουργίας - Τα κάτω, πάνωΘεραπείες στυτικής δυσλειτουργίας - Τα κάτω, πάνω
Θεραπείες στυτικής δυσλειτουργίας - Τα κάτω, πάνωInstitute for the Study of Urologic Diseases
 

Mehr von Institute for the Study of Urologic Diseases (20)

14ο Σχολείο Ουρολογίας - Uroschool 2021 | Web Scientific Event
14ο Σχολείο Ουρολογίας - Uroschool 2021 | Web Scientific Event  14ο Σχολείο Ουρολογίας - Uroschool 2021 | Web Scientific Event
14ο Σχολείο Ουρολογίας - Uroschool 2021 | Web Scientific Event
 
Andrology Update 2020 | Διαγνωστικά και Θεραπευτικά Πρωτόκολλα στην Ανδρολογί...
Andrology Update 2020 | Διαγνωστικά και Θεραπευτικά Πρωτόκολλα στην Ανδρολογί...Andrology Update 2020 | Διαγνωστικά και Θεραπευτικά Πρωτόκολλα στην Ανδρολογί...
Andrology Update 2020 | Διαγνωστικά και Θεραπευτικά Πρωτόκολλα στην Ανδρολογί...
 
13ο Σχολείο Ουρολογίας | Πρόγραμμα
13ο Σχολείο Ουρολογίας | Πρόγραμμα13ο Σχολείο Ουρολογίας | Πρόγραμμα
13ο Σχολείο Ουρολογίας | Πρόγραμμα
 
11ο Σχολείο Ουρολογίας | UroSchool 2018
11ο Σχολείο Ουρολογίας | UroSchool 201811ο Σχολείο Ουρολογίας | UroSchool 2018
11ο Σχολείο Ουρολογίας | UroSchool 2018
 
ΣΥΝΟΠΤΙΚΟ ΠΡΟΓΡΑΜΜΑ | Uroschool 2018
ΣΥΝΟΠΤΙΚΟ ΠΡΟΓΡΑΜΜΑ | Uroschool 2018  ΣΥΝΟΠΤΙΚΟ ΠΡΟΓΡΑΜΜΑ | Uroschool 2018
ΣΥΝΟΠΤΙΚΟ ΠΡΟΓΡΑΜΜΑ | Uroschool 2018
 
Andrology update 2017 | Πρόγραμμα
Andrology update 2017  | Πρόγραμμα Andrology update 2017  | Πρόγραμμα
Andrology update 2017 | Πρόγραμμα
 
10ο Ελληνικό Διαδραστικό Σχολείο Ουρολογίας | Πρόγραμμα
10ο Ελληνικό Διαδραστικό Σχολείο Ουρολογίας | Πρόγραμμα 10ο Ελληνικό Διαδραστικό Σχολείο Ουρολογίας | Πρόγραμμα
10ο Ελληνικό Διαδραστικό Σχολείο Ουρολογίας | Πρόγραμμα
 
2nd Andrology Update 2016
2nd Andrology Update 20162nd Andrology Update 2016
2nd Andrology Update 2016
 
9ο Ελληνικό Διαδραστικό Σχολείο Ουρολογίας | Πρόγραμμα `
9ο Ελληνικό Διαδραστικό Σχολείο Ουρολογίας | Πρόγραμμα `9ο Ελληνικό Διαδραστικό Σχολείο Ουρολογίας | Πρόγραμμα `
9ο Ελληνικό Διαδραστικό Σχολείο Ουρολογίας | Πρόγραμμα `
 
Κλινικές δεξιότητες στην Ανδρολογία - Andrology Update 2016 | Πρόγραμμα
 Κλινικές δεξιότητες στην Ανδρολογία - Andrology Update 2016 | Πρόγραμμα Κλινικές δεξιότητες στην Ανδρολογία - Andrology Update 2016 | Πρόγραμμα
Κλινικές δεξιότητες στην Ανδρολογία - Andrology Update 2016 | Πρόγραμμα
 
5o Κλινικό Φροντιστήριο Λειτουργικής Ουρολογίας :: Andrology Update 2015
5o Κλινικό Φροντιστήριο Λειτουργικής Ουρολογίας :: Andrology Update 20155o Κλινικό Φροντιστήριο Λειτουργικής Ουρολογίας :: Andrology Update 2015
5o Κλινικό Φροντιστήριο Λειτουργικής Ουρολογίας :: Andrology Update 2015
 
Τελικό πρόγραμμα 8ου Σχολείου Ουρολογίας
Τελικό πρόγραμμα 8ου Σχολείου ΟυρολογίαςΤελικό πρόγραμμα 8ου Σχολείου Ουρολογίας
Τελικό πρόγραμμα 8ου Σχολείου Ουρολογίας
 
Newsletter
NewsletterNewsletter
Newsletter
 
Θεραπείες στυτικής δυσλειτουργίας - Τα κάτω, πάνω
Θεραπείες στυτικής δυσλειτουργίας - Τα κάτω, πάνωΘεραπείες στυτικής δυσλειτουργίας - Τα κάτω, πάνω
Θεραπείες στυτικής δυσλειτουργίας - Τα κάτω, πάνω
 
Therapies for Erectile Dysfunction
Therapies for Erectile DysfunctionTherapies for Erectile Dysfunction
Therapies for Erectile Dysfunction
 
Υποτροφία ΕΟΕ
Υποτροφία ΕΟΕΥποτροφία ΕΟΕ
Υποτροφία ΕΟΕ
 
Hatzichristou_HPV
Hatzichristou_HPVHatzichristou_HPV
Hatzichristou_HPV
 
HPV
HPVHPV
HPV
 
HPV Επικίνδυνος σεξουαλικός επισκέπτης
HPV Επικίνδυνος σεξουαλικός επισκέπτηςHPV Επικίνδυνος σεξουαλικός επισκέπτης
HPV Επικίνδυνος σεξουαλικός επισκέπτης
 
UroOncology 2014
UroOncology 2014UroOncology 2014
UroOncology 2014
 

Αντικαταθλιπτικα

  • 2. DEPRESSION  Types  Symptoms  Diagnosis  Causes  Treatment
  • 3. TYPES OF DEPRESSION  Major depression  Chronic depression (Dysthymia)  Atypical depression  Bipolar disorder/Manic depression  Seasonal depression (SAD)
  • 4. SYMPTOMS  persistently sad, anxious, or empty moods  loss of pleasure in usual activities (anhedonia)  feelings of helplessness, guilt, or worthlessness  crying, hopelessness, or persistent pessimism  fatigue or decreased energy  loss of memory, concentration, or decision-making capability  restlessness, irritability  sleep disturbances  change in appetite or weight  physical symptoms that defy diagnosis and do not respond to treatment (especially pain and gastrointestinal complaints)  thoughts of suicide or death, or suicide attempts  poor self-image or self-esteem (as illustrated, for example, by verbal self-reproach)
  • 5. DIAGNOSIS  Extensive patient and family history  Blood test for hypothyroidism  Current medication  DSM-IV  One of the first two symptoms  Five other symptoms
  • 6. CAUSES OF DEPRESSION  Genetics  Death/Abuse  Medications
  • 7. TREATMENT FOR DEPRESSION  Psychotherapy  Electroconvulsive therapy  Natural alternatives  Medication  SSRIs  MAOIs  TCAs  SNRIs  NDRIs  TeCAs
  • 8. NEUROTRANSMITTERS AND THE CATECHOLAMINE HYPOTHESIS  Neurotransmitters pass along signal  Smaller amount of neurotransmitters causes depression
  • 9. MONOAMINE OXIDASE (MAO) AND DEPRESSION  MAO catalyze deamination of intracellular monoamines  MAO-A oxidizes epinephrine, norepinephrine, serotonin  MAO-B oxidizes phenylethylamine  Both oxidize dopamine nonpreferentially  MAO transporters reuptake extracellular monoamine
  • 10. MONOAMINE OXIDASE INHIBITORS (MAOIS)  History  Isoniazid  Iproniazid  Current Drugs  Mechanism of Action  Side Effects Isoniazid Iproniazid
  • 11. MAOIS ON THE MARKET  MAO Inhibitors (nonselective)  Phenelzine (Nardil)  Tranylcypromine (Parnate)  Isocarboxazid (Marplan)  MAO-B Inhibitors (selective for MAO-B)  Selegiline (Emsam)
  • 12. MAOIS MECHANISM OF ACTION  MAO contains a cysteinyl-linked flavin  MAOIs covalently bind to N-5 of the flavin residue of the enzyme
  • 13.
  • 15. MAOIS SIDE EFFECTS  Side effects have put MAOIs in the second or third line of defense despite superior efficacy  MAO-A inhibitors interfere with breakdown of tyramine  High tyramine levels cause hypertensive crisis (the “cheese effect”)  Can be controlled with restricted diet  MAOIs interact with certain drugs  Serotoninsyndrome (muscle rigidity, fever, seizures)  Pain medications and SSRIs must be avoided
  • 16. THE RECEPTOR SENSITIVITY HYPOTHESIS  Supersensitivity and up-regulation of post- synaptic receptors leads to depression  Suicidal and depressed patients have increased 5HT-α2 receptors
  • 17. TRICYCLIC ANTIDEPRESSANTS (TCAS)  History  Imipramine  Current Drugs  Mechanism of Action  Side Effects Imipramine
  • 18. TCAS ON THE MARKET  Amitriptyline  Desipramine (Norpramin)  Doxepin (Sinequan)  Imipramine (Tofranil, Tofranil-PM)  Nortriptyline (Pamelor)  Protriptyline (Vivactil)  Trimipramine (Surmontil)
  • 19. TCAS MECHANISM OF ACTION  TCAs inhibit serotonin, norepinephrine, and dopamine transporters, slowing reuptake  TCAs also allow for the downregulation of post- synaptic receptors  All TCAs and SSRIs contain an essential amino group that appears to interact with Asp- 98 in hSERT
  • 20. TCAS SIDE EFFECTS  Muscarinic M1 receptor antagonism - anticholinergic effects including dry mouth, blurred vision, constipation, urinary retention and impotence  Histamine H1 receptor antagonism - sedation and weight gain  Adrenergic α receptor antagonism - postural hypotension  Direct membrane effects - reduced seizure threshold, arrhythmia  Serotonin 5-HT2 receptor antagonism - weight gain (and reduced anxiety)
  • 21. TCAS SIDE EFFECTS  Nonselectivity results in greater side effects  TCAs can also lead to cardiotoxicity  Increased LDH leakage  Slow cardiac conduction  High potency can lead to mania  Contraindicated with persons with bipolar disorder or manic depression
  • 22. TETRACYCLIC ANTIDEPRESSANTS (TECAS)  Current Drugs  Mirtazapine (Remeron)  Mechanism of Action  Same as TCAs  Side Effects
  • 23. SELECTIVE SEROTONIN REUPTAKE INHIBITORS  Most commonly prescribed class  Current drugs  Mechanism of action  Side effects Serotonin
  • 24. SSRIS ON THE MARKET  citalopram (Celexa)  dapoxetine (Priligy)  escitalopram (Lexapro)  fluoxetine (Prozac)  fluvoxamine (Luvox) Fluoxetine 1:1  paroxetine (Paxil)  sertraline (Zoloft)  zimelidine (Zelmid) (discontinued)  indalpine (Upstene) (discontinued) Sertraline
  • 25. SSRIS MECHANISM OF ACTION  Exact mechanism remains uncertain  Ser-438 residue in the human serotonin transporter (hSERT) appears to be a determining factor in SSRI potency  Antidepressants interact directly with hSERT  http://www.mayoclinic.com/health/antidepressants/MM0066
  • 27. SSRIS SIDE EFFECTS  Many disappear within 4 weeks (adaption phase)  Side effects more manageable compared to MAOIs and TCAs  Sexual side effects are common  SSRI cessation syndrome  Brainzaps  Sexual dysfunction
  • 28. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)  Slightly greater efficacy than SSRIs  Slightly fewer adverse effects than SSRIs  Current drugs  Venlafaxine (Effexor)  Duloxetine (Cymbalta)  Mechanism of Action  Verysimilar to SSRIs  Works on both neurotransmitters Venlafaxine 1:1  Side effects Duloxetine  Similar to SSRIs  Suicide
  • 29.
  • 30. NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITORS (NDRIS)  Current drugs  Bupropion (Wellbutrin)  Mechanims of Action  Similar to SSRIs and SNRIs  More potent in inhibiting dopamine  Also anα3-β4 nicotinic antagonist Bupropion 1:1  Adverse effects  Lowers seizure threshold  Suicide  Does not cause weight gain or sexual dysfunction (even used to treat the two)
  • 31. REFERENCES  http://ajp.psychiatryonline.org/cgi/reprint/157/11/1901  http://www.webmd.com/depression/  http://pn.psychiatryonline.org/content/41/24/21.full  http://www.mayoclinic.com/health/maois/MH00072  http://www.springerlink.com/content/b9b8668ff59f89d7/fulltext.pdf  http://www.emsam.com/pi_emsam.pdf  http://www.nevdgp.org.au/info/topics/depression_theory.htm  http://www.uspharmacist.com/content/t/psychotropic_disorders/c/11467/  http://www.jbc.org/content/284/15/10276.full.pdf+html  http://www.aafp.org/afp/981200ap/cadieux.html  http://www.mayoclinic.com/health/antidepressants/MH00071  http://books.google.com/books? id=R0W1ErpsQpkC&pg=PA565&lpg=PA565&dq=tcas+mechanism+of+action&source=bl&ots=oAS le2Z- pr&sig=36CB_3JY4uD3LIYvqXWmAb3nliY&hl=en&ei=HzfFS9OrB4Tu9gTD6_ixDg&sa=X&oi=bo ok_result&ct=result&resnum=8&ved=0CCoQ6AEwBw#v=onepage&q=tcas%20mechanism%20of %20action&f=false  http://www.informaworld.com/smpp/content~content=a916036122&db=all

Hinweis der Redaktion

  1. Major depression – recurring and disabling. Symptoms must last for at least two weeks and impair one ’s ability to interfere with a person's ability to work, sleep, study, eat, and enjoy once-pleasurable activities. Chronic depression – less disabling than major depression, but symptoms can last longer, sometimes being unhappy for two years. More common in women, affects 10.9 million people. Atypical depression, rather than the other two, is characterized less by pervasive sadness and more by overeating, oversleeping, sensitivty to rejection Bipolar/manic depression oscillates between major depression and epsidoes of mania (extreme elation), Bipolar I – episode of mania with or without depression. Bipolar II – episode of depression with episode of hypomania or mania. Seasonal depression (SAD) – often occurs wehre winters are short or there is a big change in the amount of sunlgiht, and often treated with light therapy.
  2. MUST HAVE one of the top two AT LEAST five of the other symptoms Nearly DAILY For at least TWO WEEKS
  3. Doctor will ask many questions about personal mood, new behaviors, changes in routine Check blood and current drugs to rule out other factors (hypothyroidism, drug side effects) Drugs like antihypertensives, oral contraceptives, and Accutane for acne can cause depression BIG THING IS DISRUPTION IN FUNCTIONING
  4. Psycotherapy/talk therapy – especially useful when combined with meds. Goal is to teach good coping skills for every day stressors ECT – electric shock is applied to scalp through electrodes, results in seizure in the brain. Fast and effecitve in patients with depression or suicidal thoughts (good for suicide bc doesn ’t have the same delayed onset as meds). Usually given up to three times a week for two to four weeks Natural alternatives – St. John ’s wort (sold in teas and tablets, and in diet pills) not good for severe depression but can help mild depression
  5. SYNAPSE: Neurotransmitter passes along synapse from inside storage vesicles through transporters in the presynaptic cell to receptors in the post synaptic cell. Monoamine hypohtesis suggests that small amount of neurotransmitter causes depression
  6. Both early drugs developed in sixties for anti tuberculosis but found to have antidepressant effects, got off market due to toxicity
  7. Phenelzine – major depression Tranylcypromine – major depression Isocarboxazid – major depression Selegiline – comeback of MAOI (MAO-B inhibitor, more selective, loses selectivity at high doses) because no side effects from diet. Used primarily for treatment for Parkinson ’s disease (also approved for major depression) – shows significant improvenemnt when taken with L-DOPA
  8. MAOIs bind to the N-5 of the flavin residue if MAO, which prevents MAO from catalyzing the oxidative deamination of the monoamine, increasing their intracellular concentration so more can be released.
  9. Bold ones are most common
  10. Major side effects have kept MAOI use limitied HUGE PITFALL IS DIETARY RESTRICTION Must avoid foods with high levels of tyramine like avocados, bananas, aged cheese, certain meats and wines This is however not seen with selegiline because that is a MAO-B inhibitor, and since tyramine displaces NOREPINEPHRINE from storage vesicles, it effects MAO-A more Serotonin syndrome is caused by drug interactions with herbal weight loss supplement (St John ’s wort) and SSRIs and Pain meds like tramadol and meperidine
  11. Imipramine was first tried as an antipsychoti drug for schizophrenia, proved to be insufficient but proved to have antidepressant qualities, in the 50s around the same time as MAOIs. Imipramine is very good for severe depression, but it ’s almost too good – also causes hypomania and mania
  12. Side effects have made them second line of defense to SSRIs but they are good for treatment resistant depression bc they are so strong. Amitriptyline – most widely used, most effectve Desipramine – active metabolite of imipramine, used for neuropathic pain Doxepin – used for depression and insomnia Imipramine – used for major depression and enuresis Nortriptyline – same thing Protriptyline – depression UNIQUE BECAUSE IT IS ENERGIZING rather than sedating Trimipramine – depression, insomnia, and pain
  13. Less selective in which cells they target, will prevent serotonin, norepinephrine, and dopamine reuptake
  14. Also first rationally designed drug class, up until the 70s the antidepressants were sort of found by accident Serotonin is also referred to as 5-hydroxytryptamine
  15. More trade names once patent is over but I kept original trade names Citalopram: Major depression Dapoxetine: Premature Ejaculation Escitalopram: Major depression and various other anxiety disorders Fluxoetine: Major depression, OCD, bulimia, etc Fluvoxamine: OCD Paroxetine: Major depression or anxiety Sertraline: Major depression or anxiety Zimelidine had neurological problems like Guillan Barre Indalpine had problems with fetal low WBC
  16. The drug binds in the residue to prevent the presynaptic serotonin transporter from reuptaking the serotonin neurotransmitter. This increases extracellular concentration of serotonin, allowing more messages to be passed along. Over time, this also leads to the downregulation of the postsynaptic receptors so they are fewer and less sensitive, so they more transmittance.
  17. Many side effects go away onec the body gets used to the drug because the drug takes sometime tos tart working Sexual side effects are common (ED, low libido) due to stimuatlion of 5-HT2 receptors leading to less release of dopamine
  18. Venlafaxine is a racemix mixture While SSRIs are less potent than the other classes of drugs, they have more manageable side effects so they ’re considered better The mechanism is similar to SSRIs, as are the side effects. However, the rate of suicide for SNRIs has been debateable, especially venlafaxine. Finnish study showed Ven increased suicide risk 1.6 times compared to no treatment while Fluoxetine halved it. FDA study showed 5-fold increase in <25 so it is contraindicated in adolescents.
  19. Bupropion is a racemic mixture